Chris Newmarker’s Post

𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 (2011-2023)   Historically Medtronic reported its revenue with the following breakdown: 1- Cardiovascular 2- Restorative Therapies   The flowing are some the highlights of #Medtronic over the years.   2011: Omar Ishrak becomes the new CEO and Chairman of Medtronic. During his time, he doubles Medtronic revenue and valuation. 2013: Medtronic separates “Diabetes” from is “Restorative Therapies” and turns it into a stand-alone division. 2014: Medtronic acquires Covidien (Medtronic Minimally Invasive Therapies Group) for $42.9B. After the acquisition, Medtronic adds “Minimally Invasive Therapies” to its revenue breakdown. Today Covidien accounts for roughly one third of Medtronic #revenue. 2016: Medtronic becomes top #medicaldevice company by revenue. To this date, Medtronic maintains this position. 2020: Geoff Martha becomes the new CEO and Chairman of Medtronic. 2020: Medtronic changes its “Minimally Invasive Therapies” division to “Medical Surgical” and “Restorative Therapies” to “Neuroscience”.   Today Medtronic breaks down its revenue ($31.2B) into the following four divisions: 1. Cardiovascular ($11.6B), 2. Medical Surgical ($8.4B), 3. Neuroscience ($9B) 4. Diabetes ($2.3B).   Over the last few years Medtronic has shown steady growth in almost all its divisions. The acquisition of #Covidien has also proved to be very successful. In addition to the Top-line growth, Medtronic has also shown steady increase in its Bottom-line, thanks to its strong economics. Today, Medtronic is the top medical device company by revenue followed by Johnson & Johnson MedTech and Siemens Healthineers.   Combination of having the highest revenue and high profit margin, has made Medtronic one the most valued medical companies. Today Medtronic has a market cap comparable to that of Siemens Healthineers, GE HealthCare, and Philips combined ($110B vs $65B + $40B + $20B). Would be interesting to see if Medtronic can maintain its top position in coming years.

𝒄𝒂𝒏𝒏𝒖𝒍𝒂 𝒎𝒂𝒓𝒌𝒆𝒕 𝒊𝒔 𝒆𝒔𝒕𝒊𝒎𝒂𝒕𝒆𝒅 𝒕𝒐 𝒃𝒆 𝒂𝒓𝒐𝒖𝒏𝒅 $162.1 𝒎𝒊𝒍𝒍𝒊𝒐𝒏 𝒊𝒏 2022 𝒂𝒏𝒅 𝒊𝒔 𝒑𝒓𝒐𝒋𝒆𝒄𝒕𝒆𝒅 𝒕𝒐 𝒓𝒆𝒂𝒄𝒉 $335 𝒎𝒊𝒍𝒍𝒊𝒐𝒏 𝒃𝒚 2032, 𝒔𝒉𝒐𝒘𝒄𝒂𝒔𝒊𝒏𝒈 𝒂 𝒔𝒕𝒆𝒂𝒅𝒚 𝑪𝑨𝑮𝑹 𝒐𝒇 𝒂𝒑𝒑𝒓𝒐𝒙𝒊𝒎𝒂𝒕𝒆𝒍𝒚 6.7% ➡️ 𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑰𝒏𝒇𝒐𝒓𝒎𝒂𝒕𝒊𝒐𝒏 @ https://lnkd.in/gB_TMdhE #Cannula is a #flexible tube with a retractable and #sharp inner core which is inserted into a vein or an artery or in other body cavities of a patient in order to remove or delivery of #fluids for #treatment or #medical investigational procedures like infusing medication or obtaining #blood samples. ➡️ 𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @ https://lnkd.in/gURBS-iC ➡️ 𝐤𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : BMC | Becton Dickinson Company (Safety Syringes, Inc. ) | ICU Medical | Medtronic | LivaNova | Edwards Lifesciences | Terumo Medical Corporation | Teleflex | CONMED Corporation | Smith+Nephew | Boston Scientific | Gilde Healthcare | BAIHE MEDICAL TECHNOLOGY | B. Braun Group | Cardinal Health | C. R. Bard GmbH | Medline Industries, LP,

Democratizing diagnostics isn't just about expanding access to the home; it's about expanding access to underserved clinical settings as well. That's why we're so excited about our distribution agreement with Sekisui. As the best-value molecular COVID test available directly to consumers, our platform's potential in the home is clear. But we're also set to make a significant impact in clinical settings. The Metrix platform offers the same accuracy as a $20,000 point-of-care instrument at a fraction of the cost—just $25 per test, with our reader available for $35 in our starter bundle. Our approach is surprisingly straightforward in the point-of-care world: you buy it, you own it. No long-term contracts needed. This affordability and flexibility are essential in bringing advanced diagnostics to more people and places. Moreover, our reader already has all the hardware needed for seamless integration with any Electronic Medical Record (EMR) system, mirroring the capabilities of much more expensive options. It’s not just about having the technology; it’s about making it accessible and user-friendly. Molecular testing should be accessible to all, not just the wealthiest or most well-equipped clinics. Through our partnership with Sekisui, we’re making big strides in this direction. https://lnkd.in/gKvh89q2

Top 10 Medical Device Technologies Market worth $577.5 billion in 2027 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dDR65Cib The global Top 10 #medicaldevice technologies market is estimated at USD 577.5 billion in 2027 and is projected to reach USD 437.4 billion by 2022, at a CAGR of 5.7% from 2022 to 2027. Abbott Roche Diagnostics UK & Ireland Roche Diagnostics Nederland Roche Diabetes Care Koninklijke Kentalis Philips Siemens Healthineers  Stryker Boston Scientific Johnson & Johnson  Medtronic  Smith+Nephew GE HealthCare 

Abbott to compete with Medtronic in EU dual-chamber leadless pacemaker market: GlobalData - https://bit.ly/4c3w6ni | #Abbott #Alveir_DR #dual_chamber_leadless_pacemaker_market #GlobalData #Medtronic

📈 The MedTech Sprint Continues! ⚡ Boston Scientific, Dexcom, and Edwards Lifesciences are on the starting blocks to share their Q1 feats this week. 🏁 Last week, J&J, Abbott, and Intuitive Surgical set a brisk pace with robust volumes 🌍. The buzz now? It's Farapulse by Boston Scientific - a game-changer in the PFA domain with eyes peeled for their market rivalry with Medtronic 👀. Dexcom's up Thursday, chasing Abbott's 20% jump in CGM sales. With the G7 device's traction and a looming OTC CGM breakthrough, Stelo, growth prospects look sweet. 📊📈 Closing the week, Edwards Lifesciences awaits the TAVR market pulse post-Medtronic's trial buzz. With a steady TAVR demand, will they meet their high bar of 8-10% growth? ⏳ As always, it's about innovation, market position, and the bold steps shaping HealthTech's future. Any thoughts on these impending updates? Drop a comment, let's chat! 👇 #MedTech #Earnings #HealthTechInnovation

𝗪𝗼𝗺𝗲𝗻𝘀 𝗵𝗲𝗮𝗹𝘁𝗵 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗺𝗮𝗿𝗸𝗲𝘁 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/dPA88ndT The global womens health diagnostics market in terms of revenue was estimated to be worth $25.0 billion in 2020 and is poised to reach $36.6 billion by 2025, growing at a CAGR of 7.9% from 2020 to 2025 Quest Diagnostics Hologic, Inc. Siemens F. Hoffmann-La Roche Ltd Abbott BD General Electric Company PerkinElmer, Inc. KONINKLIJKE PHILIPS ELECTRONICS NV bioMérieux Cardinal Health SuperSonic Imagine FUJIFILM Holdings America Corporation Guided Therapeutics, Inc. Dialab GmbH Carestream MedGyn Products, Inc. Cook Medical Osteometer MediTech, Inc Samsung NeuroLogica

📢 Medtronic gets FDA approval for SynchroMed III intrathecal drug delivery system SynchroMed III is a targeted drug delivery (TDD) platform, intended to reduce the symptoms by delivering medication directly to the fluid surrounding the spinal cord. TDD therapy is a safe and effective way to manage chronic pain, cancer pain or severe spasticity, with fewer side effects and more clinician control than systemic medication. The system features a new ‘refill only’ physician workflow for effective programming, improved electronics that allow updating after implant, and enhanced cybersecurity for patient data protection. Also, the new-generation system continues several mid-generation durable design enhancements from the SynchroMed II pump, for long-term safety and reliability. Medtronic intends to start commercialising its SynchroMed III system later this year. Medtronic Pain Interventions vice president and general manager David Carr said: “Medtronic has offered targeted drug delivery therapy for over 30 years, and we continue to further enhance this technology.” “The SynchroMed III system brings forward several important developments and represents another step forward in our commitment to delivering solutions that alleviate pain and improve lives through innovative medical technology.” Read more online: bit.ly/3Qb5IiK 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medtronic #painmanagement

𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐑𝐞𝐭𝐫𝐚𝐜𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐓𝐫𝐞𝐧𝐝𝐬 Download PDF Brochure: bit.ly/3xhpiDs The size of global #surgical_retractors_market in terms of revenue was estimated to be worth USD 1.9 billion in 2022 and is poised to reach USD 2.8 billion by 2027, growing at a CAGR of 6.7% from 2022 to 2027. Becton, Dickinson and Company, B. Braun Melsungen Aktiengesellschaft, Integra LifeSciences, Teleflex, Medtronic, Johnson & Johnson, Stryker, Henry Schein, Mediflex, MEDLINE INDUSTRIES INC, Bausch Health Companies Inc., THOMPSON SURGICAL ASSOCIATES, INCORPORATED, BR Surgical, THE COOPER COMPANIES GLOBAL HOLDINGS LP, Innomed, Terumo Medical Corporation, Globus Medical, Halma plc, Enovis, CONMED Corporation #SurgicalRetractors #MedicalDevices #SurgicalInstruments #HealthcareInnovation #MedicalEquipment #SurgeryTools #HealthcareTechnology #SurgicalMarket #MedicalMarket

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗜𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗔𝗰𝗰𝗲𝘀𝘀 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Intravenous Access Devices Market Size, Share & Trends Analysis Report By Type (Intravenous Catheters, Intravenous Infusion Pumps, Intravenous Needles), By Application (Hospitals, Clinics, ASCs, Dialysis centers, Home care), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dz7GYnwi 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Access Vascular, Inc. Baxter International Inc.. AngioDynamics BKK B. Braun Melsungen AG  B. Braun Group Baxter International Inc.,  BD CareFusion  Cook Medical Medtronic  COVIDIEN LP  Edwards Lifesciences  Fresenius Medical Care Hospira.,  ICU Medical Medical Components, Inc. Medtronic Navilyst Medical Manufacturing,  New England Vascular Access Nipro Medical Corporation,  PEROUSE A Vygon company RyMed Technologies, LLC Siemens Healthineers  Smiths Medical,  Teleflex Terumo Medical Corporation Veriphi